1 min read
Add as a preferred source on GoogleEMA Panel Recommends Expanded Use of Merck’s Enflonsia in Europe
The Committee for Medicinal Products for Human Use backed a broader indication for the RSV prevention treatment, whose active ingredient is clesrovimab.
The Committee for Medicinal Products for Human Use, part of the European Medicines Agency (EMA), recommended approval of an expanded indication for Merck’s Enflonsia (clesrovimab), an RSV prevention treatment.
The endorsement moves the proposed change through the European review process toward approval.
Riza Dagoc
Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.